Saint-Martin-de-Re, France
Saint-Martin-de-Re, France

ESCP Europe is a business school with campuses in Paris, London, Berlin, Madrid, and Turin. Established in 1819, it is the oldest business school in the world.Its programmes are triple-accredited by the international AMBA, EQUIS, and AACSB. The school has many notable alumni in business and politics, such as Patrick Thomas , a former Prime Minister of France, Jean-Pierre Raffarin and the EU Commissioner for Internal Market and Services Michel Barnier. ESCP Europe has a total of 45000 alumni all over the world. Wikipedia.

Time filter
Source Type

News Article | May 11, 2017

LYON, France--(BUSINESS WIRE)--ENYO Pharma (Paris, a biopharmaceutical company currently focused on developing treatments for viral infections, has today announced that it is strengthening its business team with the appointment of a CFO and a VP Corporate Development and Strategy, both individuals having strong experience in the pharmaceutical businesses. Jacky Vonderscher, Chief Executive Officer of ENYO Pharma commented, "We are delighted to welcome these two personalities whose solid experience and established skill sets will be crucial in supporting our international development. They will provide major contributions to developing and executing our Corporate strategy and help accelerate our aggressive Business plan. This strategy focuses initially on our flagship EYP001 project, an FXR agonist for the treatment of chronic Hepatitis B, and for which we are also considering other indications such as NASH. In addition, the Company plans to evaluate all our options with new therapeutic approaches to other infectious diseases and in other significant clinical areas like Oncology". Pascale Boissel will be responsible for all financial and supporting activities at ENYO Pharma. Pascale is a specialist in finance, corporate structuring and operations with 25 years of experience. Before joining ENYO Pharma, she served as Deputy CEO and Head of Finance & Administration of the Technology Research Institute BIOASTER, an independent non-profit organization developing collaborative research programs in the fields of infectious disease and microbiology. In 2009, she joined the biotechnology company Ipsogen and served as CFO, contributing to the reorganization of the company’s US operations. She played a major role in the transaction that led to Ipsogen’s acquisition in 2011 by Qiagen. Earlier in her career Pascale served as VP Finance in business control and group transactions in several CAC 40 publicly listed French groups, and in auditing and corporate finance consultancy at Price Waterhouse Coopers. Nicolas Guyon-Gellin will be responsible for Corporate development and strategy at ENYO Pharma. As an MD with a strong experience in financial markets he brings to ENYO Pharma his valuable global expertise of the Healthcare markets. Before joining ENYO Pharma, he worked as an equity research analyst for Morgan Stanley based in London covering various sized listed companies and was involved in various Corporate banking activities. Prior to this he worked for Exane BNP and Amundi where he was in charge of global pharmaceuticals investment recommendations. Nicolas graduated from Paris V University as a General Practitioner and holds a Master degree from ESCP Europe. A muti-disciplinary team of 20+ people is now working together to support the growth of ENYO Pharma. The company is dedicated to the discovery and development of new therapeutics thanks to its unique approach mimicking viral molecular mechanisms. ENYO Pharma SA has licensed a family of FXR agonists from Poxel SA and holds worldwide exclusive rights on these patented compounds. EYP001 is a small non-bile acid molecule, acting on the human nuclear hormone receptor FXR, and is developed for the oral administration in patients with Chronic Hepatitis B (CHB). FXR is a novel and promising drug target with multiple activities required for viral replication and persistence. EYP001 interferes with HBV replication in the liver at post-entry steps likely impacting transcriptional activity of cccDNA. FXR agonism by EYP001 offers the potential for more efficient suppression of the virus leading to improved, durable viral suppression and cure rates. EYP001 is in mid-stage Phase 1 clinical trials in HBV infected patients and ENYO Pharma is also currently profiling EYP001 pre-clinically in other indications such as NASH. Partial results from the first in man trial ( NCT03110276) were presented at the EASL-ILC liver meeting in Amsterdam on April 22nd. The farnesoid X receptor (FXR) is a nuclear hormone receptor, also known as the bile acid receptor, regulating several metabolic pathways and in particular controlling the fate of bile acids in the liver and intestine. It also influences the insulin sensitivity of tissues where it is highly expressed. The class of FXR agonists is gaining attention as potential therapeutic agents in hepatobiliary and metabolic diseases. FXR activation has a favourable effect on liver growth and regeneration and has already been shown to prevent and resolve liver fibrosis in rodents and humans.

News Article | December 21, 2016

LONDON, UNITED KINGDOM--(Marketwired - Dec 21, 2016) - Mark Elliott, Chairman of the Board of Kodak Alaris, today announced that Marc Jourlait has been named Chief Executive Officer (CEO) of Kodak Alaris Holdings Limited, effective January 1, 2017. Jourlait will be based in Rochester, New York, USA. Interim CEO Jeff Goodman will return to his role as Chief Operating Officer (COO) to support Jourlait during the next few months. Jourlait's arrival and Goodman's transition will position Kodak Alaris in a strong, future-facing direction to best serve its customers. "Marc is an inspirational leader with a track record of driving sustainable and profitable growth for international technology companies," said Elliott. "I am thrilled that he will join us as CEO as his experience spans both consumer and enterprise oriented companies. In his most recent role, Marc was the Deputy CEO of Navico -- the global leader in marine electronics for recreational and commercial use. Previously, Marc held leadership roles with Apple, HP, Seagate, Technicolor and Bose. Marc worked and lived in the United States, Europe and Asia to drive many successes for the global, high-growth businesses that he led." "It is an honor and privilege to join and lead Kodak Alaris," said Jourlait. "We have all of the necessary ingredients to successfully deliver on our plans: an iconic brand heritage, cool technology and innovative portfolio, new growth initiatives, and dedicated and passionate employees around the world. I cannot wait to get started at Kodak Alaris." Jourlait holds an MBA in international business from ESCP Europe in France. About Kodak Alaris Kodak Alaris is a company that is passionate about using technology to transform organizations and improve people's lives across the planet. From our document scanners and intelligent state-of-the-art software and services that power some of the world's largest companies, to our photographic paper production, printing kiosks and suite of consumer apps, we help people capture and connect with the emotional moments that define all our lives. We're on a mission to unlock the power of images and information for the world. We work behind the scenes, making the connections, pushing the boundaries of technology and helping consumers to make sense of and exploit the ever-expanding volume of data that is the hallmark of the 21st century. © 2016 Kodak Alaris Inc. The Kodak trademark and trade dress are used under license from Eastman Kodak Company.

News Article | February 15, 2017

The company announces move to further expand New York Office NEW YORK, NY--(Marketwired - February 15, 2017) - Sinequa, a leader in cognitive search and analytics, today announced that the company achieved a record performance for the fiscal year 2016 ending on December 31, 2016, including strong double-digit growth and the addition of important new customers and partners. Worldwide software bookings grew more than 51% compared to the last fiscal year. Sinequa's North American operations based in New York have registered exceptional growth, and are already generating more than 68% of the company's software business. During this period, the company's subscription-based license fees grew by 89%. As a result of the significant growth in the U.S., Sinequa will move into its expanded New York office located in the heart of the Flatiron District in March. "We are delighted to see that in the last fiscal year, our customers and partners continue to expand the use of our platform. They are realizing how strategic cognitive search and analytics can be for their business, as it has allowed them to achieve a successful digital transformation and safeguard their leadership in a highly complex and competitive environment. This digital transformation hinges on the ability of large enterprises and public organizations to extract value from their data of all kinds -- and this is where we excel," said Fabrice de Salaberry, COO of Sinequa. During fiscal year 2016, Sinequa achieved the following significant milestones: Staff Expansion During the fiscal year, Sinequa grew its worldwide team and expanded its executive leadership team with the appointment of Stéphane Kirchacker as vice president, Sales EMEA. With 20 years of sales, project management and business development experience gained in the U.S. and Europe, Kirchacker joins Sinequa from ASG Software Solutions where he was senior vice president, Business Development Infrastructure Software. Kirchacker holds an executive MBA from ESCP Europe as well as a Master degree in Artificial Intelligence from the University of Paris 6. In addition, Sinequa appointed Jeff Evernham as director of Consulting, North America. Evernham joined Sinequa from Knowledgent where he served as the practice lead for the company's Analytics and Visualization practice. Evernham has also held executive leadership positions with North Highland Data and Analytics and Synygy. He holds a Master of Engineering degree from MIT. About Sinequa Recognized as a leader in the Gartner Magic Quadrant for Enterprise Search and other analysts' reports, Sinequa provides a cognitive search and analytics platform for Fortune Global 2000 companies and government agencies. Using advanced Natural Language Processing (NLP) and Machine Learning algorithms, the solution offers insights extracted from structured and unstructured data. Millions of users in the world's largest and most information-intensive organizations, including Airbus, AstraZeneca, Atos, Biogen, UCB, Credit Agricole, Mercer, and Siemens, rely on Sinequa to put business-critical information at the fingertips of their employees. Sinequa develops its expertise and its business around the world with a broad network of technology and business partners. Sinequa is a founding sponsor of the Cognitive Computing Consortium. For more information, visit

Zhou W.,ESCP Europe | Kapoor G.,University of Florida
Decision Support Systems | Year: 2011

A fraudulent financial statement involves the intentional furnishing and/or publishing of false information in it and this has become a severe economic and social problem. We consider Data Mining (DM) based financial fraud detection techniques (such as regression, decision tree, neural networks and Bayesian networks) that help identify fraud. The effectiveness of these DM methods (and their limitations) is examined, especially when new schemes of financial statement fraud adapt to the detection techniques. We then explore a self-adaptive framework (based on a response surface model) with domain knowledge to detect financial statement fraud. We conclude by suggesting that, in an era with evolutionary financial frauds, computer assisted automated fraud detection mechanisms will be more effective and efficient with specialized domain knowledge. © 2010 Elsevier B.V. All rights reserved.

Besson P.,ESCP Europe | Rowe F.,SKEMA Business School
Journal of Strategic Information Systems | Year: 2012

Twenty years after the promise of Information Systems enabling Organizational Transformation (IS-enabled OT), what have we learned? This paper reviews the literature in order to better understand this phenomenon. As specialists in IS, strategy and organizational studies, we analyze the discourse on OT found in the strategy, organizational theory and IS literature, and identify four structuring themes: organizational inertia, process, agency and performance. We apply the coding derived from these themes to a set of 62 empirical papers and discuss the results. Ten research avenues are then identified to show that IS-enabled OT is still a new frontier for strategic information systems research. © 2012 Elsevier B.V. All rights reserved.

The goal of this paper is to present a model for the joint evolution of correlated commodity forward curves. Each forward curve is directed by two state variables, namely slope and level, and the model is meant to capture both the local and global dependence structures between slopes and levels. Our framework can be interpreted as an extension of the concept of cointegration to forward curves. The model is applied to a US database of heating oil and natural gas futures prices over the period February 2000-February 2009. We find the long-run slope and level relationships between natural gas and heating oil markets, analyze the lead and lag properties between the two energy commodities, the volatilities and correlations between their daily co-movements and evaluate the robustness of these observations to the turmoil experienced by energy markets since 2003. © 2009 Elsevier B.V. All rights reserved.

The links between economic prosperity, or lack thereof, and the exploitation and use of energy and other natural resources go back to the earliest records of the human species - and in important respects even further back to when hunting and foraging characterised the earliest humanoid species. This paper surveys the challenges of resource exploitation and use, reflecting that as we exploit the most readily and cheapest resources, and extraction technology, available at the time, so the marginal returns of each tend to decline as the highest quality is depleted, costs rise, and alternatives are increasingly sought. There are few resources where this is truer than the various forms of energy which have been exploited down the ages. Many complex societies in the past have failed to make a successful transition, and the historic record demonstrates clearly the inadequacies of Solow-type growth theory. Scenarios of global energy prospects for the 21st Century need to consider the past and, in the light of it, ask whether the end of the Anthropocene Age is in sight or whether some kind of Promethean leap will come to the rescue. © 2015 Elsevier Ltd.

Ayres R.,INSEAD | Voudouris V.,ESCP Europe | Voudouris V.,ABM Analytics Ltd
Energy Policy | Year: 2014

We show that the application of flexible semi-parametric statistical techniques enables significant improvements in model fitting of macroeconomic models. As applied to the explanation of the past economic growth (since 1900) in US, UK and Japan, the new results demonstrate quite conclusively the non-linear relationships between capital, labour and useful energy with economic growth. They also indicate that output elasticities of capital, labour and useful energy are extremely variable over time. We suggest that these results confirm the economic intuition that growth since the industrial revolution has been driven largely by declining energy costs due to the discovery and exploitation of relatively inexpensive fossil fuel resources. Implications for the 21st century, which are also discussed briefly by exploring the implications of an ACEGES-based scenario of oil production, are as follows: (a) the provision of adequate and affordable quantities of useful energy as a pre-condition for economic growth and (b) the design of energy systems as 'technology incubators' for a prosperous 21st century. © 2013 Elsevier Ltd.

Nomikos N.,London Business School | Andriosopoulos K.,ESCP Europe
Energy Economics | Year: 2012

This paper investigates the behaviour of spot prices in eight energy markets that trade futures contracts on NYMEX. We consider two types of models, a mean-reverting model, and a spike model with mean reversion that incorporates two different speeds of mean reversion; one for the fast mean-reverting behaviour of prices after a jump occurs, and another for the slower mean reversion rate of the diffusive part of the model. We also extend these models to incorporate time-varying volatility in their specification, modelled as a GARCH and an EGARCH process. We compare the relative goodness of fit of the different modelling variations both in sample, using Monte Carlo simulations, as well as out-of-sample, in a Value-at-Risk (VaR) setting. Our results indicate the presence of a "leverage effect" for WTI, Heating Oil and Heating Oil-WTI crack spread, whereas for the remaining energy markets we find the presence of an "inverse leverage" effect. Also, the addition of the EGARCH specification for the volatility process improves both the in-sample fit as well as the out-of-sample VaR performance for most energy markets that we examine. © 2011 Elsevier B.V.

Voyer B.,ESCP Europe
British Journal of Health Care Management | Year: 2013

The present article critically discusses how the relations and roles of doctors and nurses have changed over the last 40 years, and how these have been re-shaped by a growing focus on improving patient care while preserving and improving the economics of the health service. It suggests that the emphasis on more efficiency and more accountability has changed both the roles and span of control of doctors and nurses. Yet, it also argues that stereotypes held by doctors and nurses about one another remain difficult to change. Managers have emerged as new actors in the healthcare system, and have contributed to these role shifts. Overall, the relation between doctors and nurses has changed, over the last 40 years, from being a relation based on status, to a more balanced one, based on mutual trust and leadership, resulting in the emergence of more complex psychological processes between the main actors of the healthcare system. © MA Healthcare L td, 2013. A ll rights reserved.

Loading ESCP Europe collaborators
Loading ESCP Europe collaborators